«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2015年第1期

页码:

41-044

栏目:

临床研究

出版日期:

2014-09-25

文章信息/Info

Title:

Relationship between brain natriuretic peptide and global registry of acute coronary events in non-ST-segment elevated acute coronary syndrome

作者:

朱 荔; 陈 韬; 陈 亮; 汪 莹; 李文文; 余 慧; 赵仙先

(第二军医大学附属长海医院心血管内科，上海 200433)

Author(s):

ZHU Li;  CHEN Tao;  CHEN Liang;  WANG Ying;  LI Wen-wen;  YU Hui;  ZHAO Xian-xian

(Department of Cardiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China)

关键词:

冠状动脉综合征; 急性; 非ST段抬高型; 脑钠尿肽; 全球急性冠状动脉事件注册评分; 预后

Keywords:

non-ST-segment elevated acute coronary syndrome;  brain natriuretic peptide;  GRACE risk score;  prognosis

分类号:

R541.4

DOI:

-

文献标识码:

A

摘要:

目的:探讨非ST段抬高型急性冠状动脉综合征（non-ST-segment elevated acute coronary syndrome，NSTE-ACS）患者血浆脑钠尿肽（brain natriuretic peptide，BNP）的水平与全球急性冠状动脉事件注册（global registry of acute coronary events，GRACE）评分及危险分层的关系，分析BNP对NSTE-ACS患者近期（6个月）发生主要不良心脏事件(major adverse cardiac event，MACE)的预测价值。方法： 入选2011年12月~2013年2月在我院心内科住院的NSTE-ACS患者194例，其中不稳定型心绞痛（unstable angina，UA）90例，急性非ST段抬高型心肌梗死（non-ST segment elevated myocardial infraction，NSTEMI）104例。入院后测定BNP及血脂水平。采用GRACE危险评分标准计算患者GRACE评分并进行危险分层，低危组59例，中危组65例，高危组75例。住院期间进行常规治疗。患者出院后随访6个月，观察终点为发生MACE的情况。结果： 将NSTE-ACS患者按GRACE评分进行危险分层，高危组BNP高于中危组和低危组（均P<0.01），中危组BNP显著高于低危组（P<0.01）。血浆BNP水平与GRACE评分呈正相关（r=0.656，P<0.05）。随着GRACE评分越高，血浆BNP水平亦增高，住院期间、随访期MACE发生率也随之增高。结论： GRACE评分越高，BNP水平越高，在NSTE-ACS患者中，联合运用GRACE评分和BNP水平检测，在对其进行早期危险分层、评估预后方面有重要临床价值。

Abstract:

AIM:To study the relationship between the global registry of acute coronary events (GRACE) risk score and level of brain natriuretic peptide (BNP) and to evaluate the value of BNP in predicting major adverse cardiac event (MACE). METHODS: A total of 194 non-ST-segment elevated acute coronary syndrome (NSTE-ACS) patients admitted to our hospital between December 2011 and February 2013 were studied, including 90 patients with unstable angina (UA) and 104 patients with non-ST segment elevated myocardial infarction (NSTEMI). Plasma levels of BNP and blood lipid were measured in all patients and GRACE risk scores were used for risk assessment. Patients were followed-up for 6 months and the incidences of new or recurrent myocardial infarction, target vessel revascularization, cardiac death, and heart failure were recorded. RESULTS: According to the GRACE risk score, 59 were low-risk patients, 65 middle-risk patients and 70 high-risk patients. Plasma BNP of patients in the high-risk group was significantly higher than in the middle- and low-risk groups (P<0.05). In addition, BNP was positively correlated with the GRACE risk score (r=0.656, P<0.05). Along with the higher GRACE risk score, plasma BNP increased as well as the incidence of MACE during hospitalization or the 6-month follow-up. CONCLUSION: Plasma BNP level parallels the GRACE risk score. Both the GRACE risk score and the plasma BNP level are valuable parameters for risk stratification in NSTE-ACS patients in early stages. Increased BNP level and higher GRACE score are also predictors for increased short-term risk of MACE.

参考文献/References

[1]Cannon CP,Brindis RG,Chaitman BR,et al.2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards)[J].Circulation,2013,127(9):1052-1089.
[2]Bawamia B,Mehran R,Qiu W,et al.Risk scores in acute coronary syndrome and percutaneous coronary intervention:a review[J].Am Heart J,2013,165(4):441-450.
[3]Bedetti G,Gargani L,Sicari R,et al.Comparison of prognostic value of echographic[corrected]risk score with the Thrombolysis in Myocardial Infarction(TIMI)and Global Registry in Acute Coronary Events(GRACE)risk scores in acute coronary syndrome[J].Am J Cardiol,2010,106(12):1709-1716.
[4]Fleisher LA,Beckman JA,Brown KA,et al.ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery[J].J Am Coll Cardiol, 2007,50(17):1707-1732.
[5]Mendez-Eirin E,Flores-Rios X,Garcia-Lopez F,et al.Comparison of the prognostic predictive value of the TIMI,PAMI,CADILLAC,and GRACE risk scores in STEACS undergoing primary or rescue PCI[J].Revista espanola de cardiologia(English ed.),2012,65(3):227-333.
[6]Clerico A,Vittorini S,Passino C.Circulating forms of the b-type natriuretic peptide prohormone:pathophysiologic and clinical considerations[J]. Adv Clin Chem,2012,58(1):31-44.
[7]Galvani M,Ferrini D,Ottani F.Natriuretic peptides for risk stratification of patients with acute coronary syndromes[J].Eur J Heart Fail,2004,6(3):327-333.
[8]Morrow DA,Scirica BM,Sabatine MS,et al.B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36(Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36)trial[J].J Am Coll Cardiol,2010,55(12):1189-1196.
[9]Jaberg L,Toggweiler S,Puck M,et al.Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes undergoing left main percutaneous coronary intervention[J].Circ J,2011,75(11):2648-2653.
[10]Tunon J,Blanco-Colio L,Cristobal C,et al.Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease[J].Am J Cardiol,2014,113(3):434-440.
[11]Widera C,Pencina MJ,Bobadilla M,et al.Incremental prognostic value of biomarkers beyond the GRACE(Global Registry of Acute Coronary Events)score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome[J].Clin Chem,2013 59(10):1497-1505.

备注/Memo

备注/Memo:

收稿日期：2014-03-18.
通讯作者：赵仙先，主任医师,主要研究冠心病的诊断与治疗研究Email：xianxian22010@163.com
作者简介：朱荔，住院医师，博士生Email：zhuxiaoli0430@qq.com 共同第一作者：陈韬，主治医师，硕士Email：ilion31@163.com

常用功能

更新日期/Last Update: 2015-01-20